Navidea Biopharmaceuticals Schedules First Quarter 2019 Earnings Conference Call and Business Update May 1, 2019
Navidea Biopharmaceuticals Announces Comparative Study to Evaluate the Potential Utility of Tilmanocept In Patients with Tuberculosis (“TB”) Apr 26, 2019
Navidea Biopharmaceuticals Receives FDA Feedback Regarding Rheumatoid Arthritis Clinical Trial Design and Provides Business Updates Apr 8, 2019
Navidea Biopharmaceuticals Data to be Presented at Society of Nuclear Medicine and Molecular Imaging Annual Meeting Apr 2, 2019
